Metagenomi Therapeutics, Inc. Common Stock
MGXMetagenomi, Inc. (MGX) is a biotechnology company focused on the development of next-generation gene editing therapies. Leveraging its proprietary platform, the company aims to create precise, safe, and effective genetic treatment solutions for a range of genetic diseases and conditions.
Company News
Metagenomi presented data at the ASGCT Annual Meeting 2025, showcasing advancements in its gene editing technologies, including compact nucleases for extrahepatic gene editing and CAST for site-specific integration of large therapeutic genes.
Metagenomi, a precision genetic medicines company, announced upcoming scientific presentations and provided updates on its gene editing technology and pipeline. The company highlighted positive results from a nonhuman primate study for its hemophilia A treatment and advancements in its CRISPR-associated transposase (CAST) systems.
Totus Medicines, a company developing small molecule medicines using DNA-encoded covalent library technology and AI/ML, has appointed Simon Harnest as its new Chief Financial Officer. This appointment comes as the company prepares to advance its lead covalent PI3Kα inhibitor, TOS-358, following positive Phase 1 results.
Metagenomi presented updated preclinical data for its hemophilia A program, including durable Factor VIII activity levels in an ongoing nonhuman primate study and positive results for its lead development candidate MGX-001.
Rosen Law Firm is encouraging Metagenomi, Inc. (MGX) investors to seek legal advice before the important November 25, 2024 deadline for a securities class action lawsuit. The lawsuit alleges that Metagenomi misled investors about its business relationship with Moderna during its IPO.
